NCT05110027View on ClinicalTrials.gov

Enpatoran Human Mass Balance and Absolute Bioavailability Study

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 5, 2021

Primary Completion Date

December 24, 2021

Study Completion Date

December 24, 2021

Conditions
Healthy
Interventions
DRUG

Enpatoran

Participants will receive single oral dose of enpatoran tablet on Day 1

DRUG

[14C]enpatoran microtracer

Participants will receive single oral dose of non-labeled enpatoran solution spiked with microtracer of \[14C\]enpatoran on Day 1 of Period 1.

DRUG

[14C]enpatoran microdose

Participants will receive intravenous \[14C\]enpatoran microdose administered at 1.5 hours after the oral dose of enpatoran on Day 1 of Period 2.

Trial Locations (1)

9702

PRA Health Sciences, Groningen

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT05110027 - Enpatoran Human Mass Balance and Absolute Bioavailability Study | Biotech Hunter | Biotech Hunter